

Lipoprotein(a) and Cardiovascular Outcomes in Patient Prediabetes or Diabetes

Diabetes Care

42, 1312-1318

DOI: [10.2337/dc19-0274](https://doi.org/10.2337/dc19-0274)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Impact of free fatty acids on prognosis in coronary artery disease patients under different glucose metabolism status. <i>Cardiovascular Diabetology</i> , 2019, 18, 134.	2.7	20
2	Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?. <i>Journal of Clinical Medicine</i> , 2019, 8, 2073.	1.0	15
3	The Association of Lipoprotein(a) Plasma Levels With Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1851-1858.	4.3	23
4	Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: a prospective, large cohort study. <i>Journal of Translational Medicine</i> , 2020, 18, 373.	1.8	9
5	Lipoprotein(a) and cardiovascular death in oldest-old (≥80 years) patients with acute myocardial infarction: A prospective cohort study. <i>Atherosclerosis</i> , 2020, 312, 54-59.	0.4	9
6	Long-term prognostic utility of low-density lipoprotein (LDL) triglyceride in real-world patients with coronary artery disease and diabetes or prediabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 152.	2.7	9
7	Association of plasma free fatty acids levels with the presence and severity of coronary and carotid atherosclerotic plaque in patients with type 2 diabetes mellitus. <i>BMC Endocrine Disorders</i> , 2020, 20, 156.	0.9	18
8	Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease. <i>Journal of Lipid Research</i> , 2020, 61, 1254-1262.	2.0	25
9	Serum lipoprotein (a) associates with a higher risk of reduced renal function: a prospective investigation. <i>Journal of Lipid Research</i> , 2020, 61, 1320-1327.	2.0	17
10	Recent trends in acute myocardial infarction among the young. <i>Current Opinion in Cardiology</i> , 2020, 35, 524-530.	0.8	22
11	Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1161-1168.	1.8	12
12	Heart-type fatty acid binding protein predicts cardiovascular events in patients with stable coronary artery disease: a prospective cohort study. <i>Annals of Translational Medicine</i> , 2020, 8, 1349-1349.	0.7	8
13	Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease. <i>Heart</i> , 2020, 106, 1228-1235.	1.2	28
14	Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease. <i>Cardiovascular Diabetology</i> , 2020, 19, 36.	2.7	24
15	The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 104.	2.7	42
16	Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 111.	2.7	24
17	Prognostic utility of heart-type fatty acid-binding protein in patients with stable coronary artery disease and impaired glucose metabolism: a cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 15.	2.7	10
18	Predicting Cardiovascular Outcomes by Baseline Lipoprotein(a) Concentrations: A Large Cohort and Long-Term Follow-Up Study on Real-World Patients Receiving Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2020, 9, e014581.	1.6	37

#	ARTICLE	IF	CITATIONS
19	Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. American Journal of Cardiology, 2020, 126, 94-102.	0.7	25
20	Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. Cardiovascular Diabetology, 2020, 19, 45.	2.7	44
21	Lipoprotein(a) in Patients With Type 2 Diabetes and Premature Coronary Artery Disease in the Coronary Care Unit. Heart Lung and Circulation, 2021, 30, 734-740.	0.2	5
22	The association between lipoprotein (a) and carotid atherosclerosis in patients with type 2 diabetes without pre-existing cardiovascular disease: A cross-sectional study. Diabetes Research and Clinical Practice, 2021, 171, 108622.	1.1	14
23	Atherogenic dyslipidaemia and cardiovascular events in patients with diabetes or pre-diabetes and stable coronary artery disease: a prospective, cohort study. BMJ Open, 2021, 11, e037340.	0.8	2
24	Prognostic value of NT-proBNP in patients with chronic coronary syndrome and normal left ventricular systolic function according to glucose status: a prospective cohort study. Cardiovascular Diabetology, 2021, 20, 84.	2.7	17
25	Visit-to-visit variability of lipid and cardiovascular events in patients with familial hypercholesterolemia. Annals of Translational Medicine, 2021, 9, 556-556.	0.7	0
26	Lipoprotein (a), hypertension, and cardiovascular outcomes: a prospective study of patients with stable coronary artery disease. Hypertension Research, 2021, 44, 1158-1167.	1.5	10
27	Effect of Lipoprotein (a) Levels on Long-term Cardiovascular Outcomes in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries. American Journal of Cardiology, 2021, 152, 34-42.	0.7	10
28	Managing dyslipidemia in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy, 2021, 22, 2221-2234.	0.9	14
29	Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study. Cardiovascular Diabetology, 2021, 20, 143.	2.7	22
30	Plasma lipoprotein(a) measured in the routine clinical care is associated to atherosclerotic cardiovascular disease during a 14-year follow-up. European Journal of Preventive Cardiology, 2022, 28, 2038-2047.	0.8	10
31	Coronary Artery Disease: Optimal Lipoprotein(a) for Survival—Lower Is Better? A Large Cohort With 43,647 Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 670859.	1.1	3
32	Association between new markers of cardiovascular risk and hepatic insulin resistance in those at high risk of developing type 2 diabetes. Endocrine, 2022, 75, 409-417.	1.1	3
33	Lipoprotein (a) and diabetes mellitus: causes and consequences. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 181-187.	1.2	13
34	Prognostic Significance of Preprocedural N-Terminal Pro-B-Type Natriuretic Peptide Assessment in Diabetic Patients With Multivessel Coronary Disease Undergoing Revascularization. Frontiers in Cardiovascular Medicine, 2021, 8, 721260.	1.1	3
35	Impact of lipoprotein(a) level on cardiometabolic disease in the Chinese population: The CHCN-BTH Study. European Journal of Clinical Investigation, 2022, 52, e13689.	1.7	4
36	Association of diabetes mellitus with clinical outcomes in patients with different coronary artery stenosis. Cardiovascular Diabetology, 2021, 20, 214.	2.7	8

#	ARTICLE	IF	CITATIONS
37	Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 104-113.	1.2	2
38	Use of cardiovascular imaging in risk re-stratification of the diabetic patient. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 122-133.	1.2	2
39	Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d'athérosclérose (NSFA). <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 828-847.	0.7	9
40	Association of Lipoprotein(a)-Associated Mortality and the Estimated Glomerular Filtration Rate Level in Patients Undergoing Coronary Angiography: A 51,500 Cohort Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 747120.	1.1	4
41	Lipoprotein (a)-mediated vascular calcification: population-based and in vitro studies. <i>Metabolism: Clinical and Experimental</i> , 2022, 127, 154960.	1.5	13
42	Baseline Low-Density-Lipoprotein Cholesterol Modifies the Risk of All-Cause Death Associated With Elevated Lipoprotein(a) in Coronary Artery Disease Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 817442.	1.1	2
43	Elevated lipoprotein(a) levels as an independent predictor of long-term recurrent events in patients with acute coronary syndrome. <i>Coronary Artery Disease</i> , 2022, Publish Ahead of Print, .	0.3	2
44	Association between triglyceride glucose index and carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China. <i>Cardiovascular Diabetology</i> , 2022, 21, 38.	2.7	25
45	Omega-3 fatty acids coordinate glucose and lipid metabolism in diabetic patients. <i>Lipids in Health and Disease</i> , 2022, 21, 31.	1.2	10
46	Elevated Lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: Insights from the REASSURE-NIRS registry. <i>Atherosclerosis</i> , 2022, 349, 183-189.	0.4	12
47	Non-alcoholic Fatty Liver Disease Is Associated With Cardiovascular Outcomes in Subjects With Prediabetes and Diabetes: A Prospective Community-Based Cohort Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 889597.	1.1	4
48	Association of C-peptide and lipoprotein(a) as two predictors with cardiometabolic biomarkers in patients with type 2 diabetes in KERCADR population-based study. <i>PLoS ONE</i> , 2022, 17, e0268927.	1.1	5
49	Lipoprotein (a) and diabetes mellitus. <i>Atherosclerosis</i> , 2022, 349, 63-71.	0.4	27
50	Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Different Metabolic Phenotypes. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	3
51	Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	10
52	Triglyceride glucose index for the detection of the severity of coronary artery disease in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	37
53	Prevalence and Characteristics of Prediabetes and Metabolic Syndrome in Seemingly Healthy Persons at a Health Check-Up Clinic. <i>Journal of Multidisciplinary Healthcare</i> , 0, Volume 15, 1585-1594.	1.1	3
54	Clinical impact of blood pressure on cardiovascular death in patients 80 years and older following acute myocardial infarction: a prospective cohort study. <i>Hypertension Research</i> , 0, , .	1.5	2

#	ARTICLE	IF	CITATIONS
55	New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e4281-e4294.	1.8	5
56	Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 382-392.	1.0	7
57	Associations of serum calcium/magnesium ratios with coronary artery disease in diabetes: a cross-sectional study. <i>Postgraduate Medicine</i> , 2023, 135, 72-78.	0.9	2
58	Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention. <i>Atherosclerosis</i> , 2022, 363, 109-116.	0.4	8
59	Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies. <i>Journal of Clinical Medicine</i> , 2022, 11, 6040.	1.0	14
60	What is responsible for acute myocardial infarction in combination with aplastic anemia? A case report and literature review. <i>World Journal of Clinical Cases</i> , 0, 10, 11955-11966.	0.3	1
61	Glucose metabolism status modifies the relationship between lipoprotein(a) and carotid plaques in individuals with fatty liver disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
62	The value of HDL subfractions in predicting cardiovascular outcomes in untreated, diabetic patients with stable coronary artery disease: An age- and gender-matched case-control study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
63	Lipoprotein(a), Cardiovascular Events and Sex Differences: A Single Cardiological Unit Experience. <i>Journal of Clinical Medicine</i> , 2023, 12, 764.	1.0	0
64	Association between cumulative lipoprotein(a) exposure and adverse cardiovascular outcomes in patients with prediabetes or diabetes. <i>IScience</i> , 2023, 26, 106117.	1.9	0
65	Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states. <i>Cardiovascular Diabetology</i> , 2023, 22, .	2.7	9
66	What Is the Role of Aspirin in Primary Prevention in Patients With Elevated Lp(a)? <i>Cardiometabolic Syndrome Journal</i> , 2023, 3, 41.	1.0	1
67	HbA1c-based rather than fasting plasma glucose-based definitions of prediabetes identifies high-risk patients with angiographic coronary intermediate lesions: a prospective cohort study. <i>Cardiovascular Diabetology</i> , 2023, 22, .	2.7	1
68	The prognostic effect of prediabetes defined by different criteria in patients with stable coronary artery disease: a prospective cohort study in Asia. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 1418-1426.	0.8	5
69	Are we seeing the light at the end of the tunnel for high lipoprotein(a)? <i>Lipoprotein(a)</i> , 2022, 1, .		0
72	Epidemiology, Control, and Cardiovascular Outcomes of Dyslipidemia in Diabetes. <i>Contemporary Diabetes</i> , 2023, , 891-913.	0.0	0
73	Clinical Care of Lipids in People with Type 1 Diabetes. <i>Contemporary Diabetes</i> , 2023, , 755-778.	0.0	0